Summary
Some clinical-label-aligned statements are present (e.g., indications, infection risk, listed adverse effects, and basic monitoring). However, many statements are not supported/assessable from the provided label excerpts (notably cost, patents, biosimilars, and specific company names/timing), and several safety/monitoring details are partially generic rather than anchored to exact label language.
Category Scores
Accurate Statements
Stelara (ustekinumab) is an injectable medication used to treat moderate to severe plaque psoriasis.
Supported by 1.1 Plaque Psoriasis (moderate to severe plaque psoriasis; STELARA indicated for adults and pediatric patients).
Stelara (ustekinumab) is an injectable medication used to treat psoriatic arthritis.
Supported by 1.2 Psoriatic Arthritis (active psoriatic arthritis; indicated for adults and pediatric patients).
Stelara (ustekinumab) is an injectable medication used to treat Crohn's disease.
Supported by 1.3 Crohn’s Disease (moderately to severely active Crohn’s disease; indicated for adults and pediatric patients).
Stelara (ustekinumab) is an injectable medication used to treat ulcerative colitis.
Supported by 1.4 Ulcerative Colitis (moderately to severely active ulcerative colitis; indicated for adult patients).
Stelara carries potential risks including serious infections.
Supported by 5.1 Infections (STELARA may increase risk of infections; avoid initiating in patients with active infection).
Patients taking Stelara may be more prone to infections.
Supported by 5.1 Infections (STELARA may increase the risk of infections).
Healthcare providers monitor for signs of infection during Stelara treatment.
Supported by 5.1 Infections (instruct patients to seek advice if signs/symptoms suggestive of infection occur while on treatment; and discontinue for serious infections).
Unsupported Statements
Precise cost figures for Stelara in 2025 and 2026 are not yet publicly available.
Not addressed in the provided label excerpts.
Stelara's cost in 2025 and 2026 will be influenced by patent expirations, the availability of biosimilars, and market competition.
Not addressed in the provided label excerpts.
The introduction of biosimilars is expected to significantly impact Stelara pricing.
Not addressed in the provided label excerpts.
Stelara's U.S. patents are set to expire.
Not addressed in the provided label excerpts.
Key patents related to Stelara are expected to expire around 2023 and 2024.
Not addressed in the provided label excerpts.
Biosimilar versions of Stelara could become available in the market in the coming years.
Not addressed in the provided label excerpts.
The availability of biosimilars could lead to price reductions for Stelara.
Not addressed in the provided label excerpts.
The entry of biosimilars typically leads to a decrease in the price of the reference biologic drug.
Not addressed in the provided label excerpts.
Biosimilars are highly similar to their reference products.
Not addressed in the provided label excerpts.
Biosimilars are approved by regulatory bodies to have no clinically meaningful differences in terms of safety, purity, and potency.
Not addressed in the provided label excerpts.
Biosimilar competition often results in more affordable treatment options for patients and healthcare systems.
Not addressed in the provided label excerpts.
Stelara is generally comparable in cost to other biologic drugs used for similar conditions, such as TNF inhibitors.
Not addressed in the provided label excerpts.
Direct side-by-side cost comparisons of Stelara are complex and depend on the specific drug, its dosage, the indication, and negotiated prices by insurance providers.
Not addressed in the provided label excerpts.
As biosimilars enter the market, the competitive landscape will shift, potentially making Stelara less expensive relative to its competitors.
Not addressed in the provided label excerpts.
Several pharmaceutical companies have been developing biosimilars for Stelara, including Samsung Bioepis.
Not addressed in the provided label excerpts.
Several pharmaceutical companies have been developing biosimilars for Stelara, including Celltrion.
Not addressed in the provided label excerpts.
Several pharmaceutical companies have been developing biosimilars for Stelara, including Amgen.
Not addressed in the provided label excerpts.
The approval and market launch dates of Stelara biosimilars will influence competitive pricing of Stelara.
Not addressed in the provided label excerpts.
Side effects of Stelara can include upper respiratory infections.
Not specifically supported by the provided adverse reactions excerpts (label excerpt lists infections generally; does not explicitly list upper respiratory infections as a named adverse reaction).
Side effects of Stelara can include headache.
Not supported by the provided adverse reactions excerpts.
Side effects of Stelara can include fatigue.
Not supported by the provided adverse reactions excerpts.
Side effects of Stelara can include injection site reactions.
Not supported by the provided adverse reactions excerpts.
Side effects of Stelara can include diarrhea.
Not supported by the provided adverse reactions excerpts.
Janssen, the manufacturer of Stelara, typically offers patient assistance programs.
Not addressed in the provided label excerpts.
Janssen patient assistance programs can help eligible patients with the cost of their medication.
Not addressed in the provided label excerpts.
Information on Janssen patient assistance programs can usually be found on the drug's official website or through healthcare providers.
Not addressed in the provided label excerpts.
Contradictions
Important Omissions
No contraindications were addressed by the AI response (e.g., clinically significant hypersensitivity to ustekinumab or excipients).
Importance:
Moderate
No label-required tuberculosis pre-treatment evaluation/monitoring details were included (5.3).
Importance:
Moderate
No immunization restriction details were included (avoid live vaccines; BCG timing).
Importance:
Moderate
No dosage/regimen information was provided (weight-based dosing, induction/maintenance timing, and route-specific schedules).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes infection risk and general monitoring, but omits several label-specific safety requirements (notably TB evaluation/monitoring and immunization guidance). It also makes multiple unsupported adverse-effect claims, which could mislead safety expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Large portions of the response address pricing/patents/biosimilars and patient assistance, none of which are supported by the provided FDA label excerpts; additionally, several adverse-effect examples are not supported by the excerpts.
Suggested Improvement
Limit statements to on-label content present in the provided label excerpts; remove or qualify non-label claims (cost/patents/biosimilars/company-specific development). For safety, include label-specific precautions such as TB evaluation/monitoring and live vaccine/BCG restrictions, and only list adverse reactions that are explicitly supported by the label excerpts.